Financial Performance - The company's operating revenue for the first half of 2021 was approximately ¥119.80 million, representing a 20.97% increase compared to ¥99.03 million in the same period last year[16]. - The net profit attributable to shareholders for the first half of 2021 was approximately ¥49.95 million, a significant turnaround from a loss of ¥36.73 million in the same period last year, marking a 235.98% increase[16]. - The basic earnings per share for the first half of 2021 was ¥0.1332, compared to a loss of ¥0.0917 per share in the same period last year, reflecting a 245.26% improvement[17]. - The weighted average return on net assets for the first half of 2021 was 7.75%, a recovery from -3.99% in the same period last year, indicating improved profitability[18]. - The company achieved total revenue of CNY 119.80 million in the first half of 2021, an increase of 20.97% compared to the same period last year[31]. - Net profit attributable to shareholders reached CNY 49.95 million, a significant increase of 235.98% year-on-year, primarily due to a share transfer agreement that generated CNY 43.50 million in gains[31]. Assets and Liabilities - The company's net assets attributable to shareholders increased by 8.07% to approximately ¥669.21 million from ¥619.26 million at the end of the previous year[16]. - The total assets of the company showed a slight increase of 0.31%, reaching approximately ¥977.66 million compared to ¥974.68 million at the end of the previous year[16]. - The company's total assets as of June 30, 2021, were CNY 977.66 million, a 0.31% increase from the beginning of the year, while total liabilities decreased by 13.41% to CNY 303.52 million[32]. - The company's total liabilities amounted to ¥91,281,881.36, a decrease from ¥131,704,959.57 in the previous year[110]. - The company's total liabilities were CNY 303,518,812.04, down from CNY 350,519,430.13, representing a decrease of approximately 13.4%[106]. Cash Flow - The company reported a net cash flow from operating activities of approximately -¥15.43 million, an improvement of 63.35% from -¥42.08 million in the same period last year[16]. - The net cash flow from operating activities improved by 63.35%, reaching approximately -15.43 million, attributed to increased cash receipts from sales[44]. - Cash inflow from operating activities was CNY 102,782,500.84, a decrease of 9.3% from CNY 113,443,981.07 in the same period last year[118]. - The net cash flow from investment activities was -CNY 3,631,528.79, compared to CNY 6,797,574.97 in the same period last year[119]. Market and Industry Trends - The global pharmaceutical R&D outsourcing ratio is expected to increase from approximately 39.5% in 2019 to 49.3% by 2023, indicating a growing trend in the CRO industry[27]. - The Chinese CRO market is projected to grow significantly, with the industry size expected to reach $43.2 billion by 2023, reflecting a compound annual growth rate of about 21.1% from 2019[27]. - The increasing demand for high-quality generic drugs and innovative drug development in China is driving the growth of the CRO industry[25]. Business Operations - The company's main business focuses on drug development and technology transfer, covering almost all disease areas including oncology, hypertension, and diabetes[23]. - The CRO service model aims to save time and costs for pharmaceutical companies by providing specialized outsourced services throughout the drug development process[24]. - The company aims to expand its service offerings in drug discovery, CMC development, clinical trials, and regulatory submissions through a one-stop outsourcing model[22]. - The company has established a nationwide clinical trial center network, enhancing its capability to conduct I-IV phase clinical trials efficiently[29]. - The company emphasizes a one-stop CRO service advantage, covering the entire drug development process from discovery to registration[28]. Employee and Management - The company employs a highly qualified team of 636 professionals, with 88% being research and development personnel, ensuring high-quality service delivery[28]. - The company implemented an employee stock option incentive plan, granting 12.10 million stock options to 162 employees during the reporting period[41]. - The management team has shown a positive trend in personal shareholding, with several executives increasing their holdings during the reporting period[100]. Regulatory and Compliance - The company has not reported any non-operational fund occupation by controlling shareholders or related parties during the reporting period[4]. - The company has committed to fair operations and compliance with disclosure obligations in any necessary related party transactions[77]. - The company confirmed that it will not engage in any business activities that compete with its listed operations, ensuring no direct or indirect competition[75]. Strategic Initiatives - The company is focusing on expanding its market presence and exploring new strategies, including potential mergers and acquisitions[68]. - The company has set a three-year shareholder return plan for 2021-2023[68]. - The company plans to issue non-public A-shares to raise funds, with a feasibility report on the use of raised funds presented[68]. Risks and Challenges - The company faces increasing market competition from both domestic and international CRO companies, which may pressure pricing and profitability[59]. - Regulatory risks are significant in the pharmaceutical R&D and manufacturing sectors, requiring the company to adapt to changing policies[60]. - The complexity of pharmaceutical R&D projects poses risks of contract termination and rising costs as the company expands its services[61]. - The ongoing impact of COVID-19, particularly the Delta variant, may adversely affect the company's operations[64].

新疆百花村股份有限公司 证券代码：600721 证券简称：*ST 百花 公告编号：2021- 052 新疆百花村股份有限公司关于参加 2021 年新疆辖区 投资者网上集体接待日暨上市公司业绩说明会活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 为便于广大投资者更深入全面地了解公司情况、发展战略、经营状况、融资 计划、股权激励、可持续发展等投资者所关心的问题，公司定于 2021 年 6 月 18 日下午 15:00 至 17:30 参加由新疆上市公司协会联合深圳市全景网络有限公司组 织开展的 2021 年新疆辖区上市公司投资者网上集体接待日活动。现将有关事项 公告如下： 本次集体接待日活动将在深圳市全景网络有限公司提供的网上平台，釆取网 络远程的方式举行，投资者可以登录全景网"投资者关系互动平台"网站 （http://ir.p5w.net/）或关注微信公众号：全景财经（微信号：p5w2012）,参与公 司本次投资者集体接待日活动，活动时间为 2021 年 6 月 18 日（星期五）15:00 至 17:30。 出席本次集体接待日的人员有：公司董事长 ...

Financial Performance - Net profit attributable to shareholders was CNY 1,071,993.40, representing a decline of 26.31% year-on-year[5] - Operating revenue for the period was CNY 47,264,446.74, an increase of 1.33% compared to the same period last year[5] - Basic earnings per share decreased by 19.44% to CNY 0.0029[5] - The company reported a net profit excluding non-recurring items of CNY 425,633.74, a significant improvement compared to a loss in the previous year[5] - The company reported a significant decrease in investment income for the current period, amounting to CNY 0.04 million, a reduction of 91.65% compared to the same period last year[15] - Operating profit for Q1 2021 was CNY 1,561,321.42, compared to CNY 1,024,934.61 in Q1 2020, indicating a growth of 52.2%[29] - The net profit for Q1 2021 was ¥614,431.60, a decrease of 30.7% from ¥885,802.02 in Q1 2020[33] - The operating profit for Q1 2021 was ¥841,495.74, down 38.2% from ¥1,362,642.26 in Q1 2020[32] - The total profit for Q1 2021 was ¥857,985.01, down 37.0% from ¥1,362,642.26 in Q1 2020[32] Cash Flow - The net cash flow from operating activities improved by 35.86%, reaching -CNY 13,620,328.17[5] - Net cash flow from operating activities for the current period was CNY -13.62 million, an improvement of CNY 7.61 million compared to the same period last year, mainly due to reduced cash payments to employees and lower tax payments[16] - The cash inflow from operating activities in Q1 2021 was ¥48,027,178.52, a decrease of 9.4% from ¥52,743,048.39 in Q1 2020[35] - The company's total cash inflow from operating activities was significantly impacted by increased payments to employees and other operational expenses, totaling 24,705,412.95 RMB in Q1 2021[38] - The total cash inflow from operating activities was 12,572,025.93 RMB, up from 4,524,293.84 RMB in the same period last year, reflecting a 178% increase[38] - The cash outflow for operating activities reached 27,802,445.08 RMB, compared to 5,116,316.98 RMB in Q1 2020, marking a 444% increase in cash outflows[38] Assets and Liabilities - Total assets at the end of the reporting period were CNY 960,827,824.81, a decrease of 1.42% compared to the end of the previous year[5] - Total liabilities as of March 31, 2021, were CNY 293.13 million, a decrease from CNY 308.24 million at the end of 2020[20] - Total assets as of March 31, 2021, amounted to CNY 714,984,479.82, slightly down from CNY 715,717,492.79 at the end of 2020[24] - Total liabilities as of March 31, 2021, were CNY 130,357,515.00, a decrease from CNY 131,704,959.57 at the end of 2020[25] - Shareholders' equity totaled CNY 584,626,964.82 as of March 31, 2021, compared to CNY 584,012,533.22 at the end of 2020, showing a slight increase[25] Shareholder Information - The total number of shareholders at the end of the reporting period was 9,702[11] - The largest shareholder, Xinjiang Hualing Industrial Trade Group Co., Ltd., held 21.20% of the shares[11] Expenses - Sales expenses for the current period were CNY 1.14 million, a decrease of CNY 0.19 million or 14.15% compared to the same period last year, primarily due to reduced sales business expenses[15] - R&D expenses for the current period were CNY 1.14 million, an increase compared to the same period last year due to expenses related to innovative drug research by a subsidiary[15] - Research and development expenses for Q1 2021 were CNY 1,139,542.38, indicating ongoing investment in innovation[29] Cash and Cash Equivalents - Cash and cash equivalents at the end of the period were CNY 41.79 million, a decrease of CNY 3.83 million or 8.40% from the beginning of the period, mainly due to reduced cash retention for operations[13] - Cash and cash equivalents decreased to CNY 4,388,814.55 from CNY 14,580,472.06 at the end of 2020, indicating a significant reduction in liquidity[23] - The total cash and cash equivalents at the end of Q1 2021 were 41,785,041.34 RMB, down from 51,123,162.82 RMB at the beginning of the quarter[37] - The company reported a cash and cash equivalents net decrease of 3,830,399.12 RMB in Q1 2021, compared to a decrease of 26,271,804.68 RMB in Q1 2020[37]

Financial Performance - The company's net profit for 2020 was -339,536,904.66 RMB, with a cumulative distributable profit of -2,018,041,645.09 RMB, leading to no cash dividend distribution for the year [4]. - The operating revenue for 2020 was 84,530,414.24 RMB, a decrease of 67.74% compared to 262,017,718.33 RMB in 2019 [17]. - The net profit attributable to shareholders for 2020 was -320 million RMB, indicating a shift from profit to loss primarily due to revenue decline and rising costs [40]. - Basic earnings per share for 2020 was -0.8202 CNY, a decrease of 1,053.72% compared to 0.0860 CNY in 2019 [19]. - The weighted average return on equity decreased by 45.26 percentage points to -41.58% in 2020 from 3.68% in 2019 [19]. - The company reported a gross loss of CNY 13.69 million for 2020 [185]. Assets and Liabilities - Total assets decreased by 24.51% to 974,684,317.02 RMB from 1,291,205,717.74 RMB in 2019 [18]. - The net asset attributable to shareholders decreased by 35.13% to 619,263,889.76 RMB from 954,695,566.45 RMB in 2019 [18]. - The company's current assets decreased to CNY 440,459,673.45 from CNY 599,439,079.01, reflecting a reduction of approximately 26.6% [197]. - Total liabilities increased slightly to CNY 350,519,430.13 from CNY 336,510,151.29, indicating a growth of about 4.0% year-over-year [198]. - The total liabilities to total assets ratio stands at approximately 36.0%, indicating a moderate level of leverage [198]. Cash Flow - The company reported a net cash flow from operating activities of -23,281,213.51 RMB, a decline of 242.60% compared to -6,795,414.33 RMB in 2019 [18]. - The company reported a net cash flow from investing activities of ¥33,625,074.48, a significant increase of 176.13% compared to -¥44,167,040.78 in the previous period [75]. - The net cash flow from financing activities decreased compared to the previous year, primarily due to repayment of bank loans [58]. Research and Development - The company has a strong R&D capability with over 700 professional service team members, including 158 with doctoral or master's degrees [37]. - The total R&D expenditure for the year was CNY 6,114,512.78, accounting for 7.23% of the company's revenue [71]. - R&D expenses increased to CNY 6.11 million, reflecting a focus on innovative drug development [57]. - The company is focusing on building a proprietary technology pipeline for innovative drugs, particularly in niche areas, to meet diverse market demands [91]. Market and Industry Trends - The CRO industry is expected to grow significantly, with global outsourcing of pharmaceutical R&D projected to increase from 39.5% in 2019 to 49.3% by 2023 [35]. - The Chinese pharmaceutical R&D service market is forecasted to grow from approximately 20.1 billion USD in 2019 to 43.2 billion USD by 2023, with a compound annual growth rate of about 21.1% [35]. - The pharmaceutical industry is experiencing a shift towards innovative drug development, with over 3,000 companies globally engaged in new drug research, indicating a growing market for CRO services in China [87]. Corporate Governance and Compliance - The company received a standard unqualified audit report from Sigma Accounting Firm [6]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties [5]. - The company has not violated any decision-making procedures for providing guarantees [5]. - The company has committed to avoiding any business activities that compete with its listed company and its subsidiaries [109]. Shareholder and Equity Information - The total share capital at the end of 2020 was 375,134,355 shares, a decrease of 6.31% from 400,386,394 shares in 2019 [18]. - The company did not distribute any cash dividends or stock bonuses in the years 2018, 2019, and 2020, with net losses of RMB 675.29 million, RMB 34.38 million, and RMB 319.77 million respectively [107]. - The total number of ordinary shareholders increased from 9,588 to 10,065 during the reporting period, representing a growth of approximately 5% [140]. Employee and Management Information - The company employed a total of 770 staff, with 42 in the parent company and 728 in major subsidiaries [163]. - The technical personnel accounted for 620 out of the total 770 employees, indicating a strong focus on technical expertise [163]. - The total pre-tax remuneration for the board members during the reporting period amounted to 452.99 million yuan [154]. Risks and Challenges - The company is at risk of delisting as it reported a negative net profit and operating revenue below 100 million RMB, triggering the delisting risk warning as per the Shanghai Stock Exchange regulations [5]. - The company faces competition from both established international players and emerging domestic CRO firms, necessitating a strategic response to maintain its market position [101].

Financial Performance - Operating revenue for the first nine months was CNY 81,620,014.02, down 59.66% year-on-year[7] - Net profit attributable to shareholders was a loss of CNY 41,881,540.74, representing a decrease of 184.05% compared to the same period last year[7] - Basic and diluted earnings per share were both CNY -0.1065, a decline of 185.54% year-on-year[8] - The company reported a net loss of CNY 101,908,886.13 attributable to shareholders, a decline of 333.08% year-on-year[7] - The company reported a net loss of 23.01 million yuan in the third quarter, with a revenue drop of 66.83% compared to the same period last year, primarily due to contract terminations[15] - Total revenue for Q3 2020 was -17,410,053.23 CNY, compared to 69,197,985.80 CNY in Q3 2019, indicating a significant decline[34] - Net profit for Q3 2020 was -5,147,302.38 CNY, compared to a net profit of 12,224,706.18 CNY in Q3 2019, representing a year-over-year decline of 142.1%[35] Cash Flow - Cash flow from operating activities for the first nine months was CNY 2,002,156.36, an increase of 105.23% compared to the same period last year[7] - Net cash flow from operating activities was 2.00 million yuan, an increase of 4,029.54 million yuan compared to the same period last year, primarily due to receiving 73.05 million yuan in compensation and arbitration fees[22] - Net cash flow from investing activities was 33.15 million yuan, an increase of 6,420.78 million yuan year-on-year, mainly due to a reduction of 67.20 million yuan in cash outflow for purchasing bank wealth management products[22] - Net cash flow from financing activities was -0.66 million yuan, a decrease of 467.08 million yuan compared to the same period last year, primarily due to a reduction in cash received from borrowings[23] - The net cash flow from operating activities for the first nine months of 2020 was ¥2,002,156.36, a recovery from a negative cash flow of ¥38,293,210.29 in the same period of 2019[43] - Total cash inflow from operating activities was 136,311,122.18 RMB, compared to 49,097,058.55 RMB in the first three quarters of 2019, indicating a significant increase[45] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,279,393,041.50, a decrease of 0.91% compared to the end of the previous year[7] - Total liabilities were 381.85 million yuan, an increase from 336.51 million yuan at the end of 2019[29] - The company's total equity attributable to shareholders was 897.54 million yuan, down from 954.70 million yuan at the end of 2019[30] - Total liabilities increased to 133,064,497.91 CNY in Q3 2020, compared to 91,109,367.03 CNY in Q3 2019, marking an increase of approximately 46%[33] - The company's total equity as of Q3 2020 was 963,921,252.95 CNY, up from 923,945,764.05 CNY in Q3 2019, showing a growth of about 4.3%[33] Operational Changes - The company terminated 29 pharmaceutical R&D contracts, resulting in a revenue reduction of 59.70 million yuan and a profit decrease of 65.99 million yuan[17] - The company plans to adjust its strategic layout towards a combination of generic and innovative drug development in response to market changes[19] - The company aims to enhance its business team and improve customer service to mitigate the impact of contract terminations and revenue declines[20] - The company has not reported any new product launches or technological advancements during this period, indicating a potential area for future growth[54] Financial Ratios and Metrics - The weighted average return on equity decreased by 9.87 percentage points to -4.56%[8] - Financial expenses surged to 17.03 million yuan, an increase of 5581.65% from 0.30 million yuan, mainly due to the recognition of unconfirmed financing costs[20] - The company's total liabilities to equity ratio indicates a leverage position that may require monitoring for financial stability[53] Other Income and Expenses - Other income decreased to 1.32 million yuan, down 43.01% from 2.32 million yuan, primarily due to reduced government subsidies[21] - The company incurred a credit impairment loss of 5,719,269.51 CNY in Q3 2020, compared to a recovery of -667,996.07 CNY in Q3 2019, indicating a significant deterioration in credit quality[35] - The company reported a financial expense of ¥15,693,623.42 in Q3 2020, significantly higher than ¥178,217.36 in Q3 2019[38]

Financial Performance - The company's operating revenue for the first half of 2020 was ¥99,030,067.25, a decrease of 25.62% compared to ¥133,148,773.65 in the same period last year[14]. - The net profit attributable to shareholders for the first half of 2020 was -¥36,734,238.36, representing a decline of 197.99% from a profit of ¥37,486,550.58 in the previous year[14]. - The basic earnings per share for the first half of 2020 was -¥0.0917, a decrease of 197.97% compared to ¥0.0936 in the same period last year[16]. - The weighted average return on net assets was -3.99%, a decrease of 8.01 percentage points from 4.02% in the previous year[16]. - The consolidated revenue of Huawai Medicine was 82.66 million yuan, down 30.30% year-on-year[26]. - The R&D revenue of Huawai Medicine was 48.08 million yuan, a decrease of 27.08 million yuan from the previous year's 75.16 million yuan[26]. - The net profit of Huawai Medicine was -26.84 million yuan, a decrease of 57.96 million yuan year-on-year[27]. - The company's main revenue decreased by 13.8 million yuan compared to the same period last year, primarily due to a reduction in order volume from policy adjustments and a decline in consistency evaluation business[29]. - Operating profit for the first half of 2020 was a loss of CNY 26,489,858.99, compared to a profit of CNY 44,428,937.19 in the first half of 2019[100]. - Net profit for the first half of 2020 was a loss of CNY 36,734,238.36, compared to a profit of CNY 37,266,141.34 in the same period of 2019[101]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥42,083,815.35, showing a slight improvement of 1.85% compared to -¥42,877,591.50 in the same period last year[14]. - The company reported a significant cash outflow of 1,666,275.84 CNY, leading to a total decrease in cash and cash equivalents of 15,546,447.54 CNY[110]. - The cash flow from operating activities was not detailed in the provided documents, indicating a potential area for further analysis[110]. - The company generated 88,844,425.57 yuan in cash from sales of goods and services, a decrease of approximately 16% from 105,809,992.11 yuan in the same period last year[106]. - The financing activities resulted in a net cash outflow of 3,114,715.52 CNY, primarily due to debt repayment of 2,700,000.00 CNY and dividend distribution of 414,715.52 CNY[110]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,252,564,144.48, down 2.99% from ¥1,291,205,717.74 at the end of the previous year[14]. - The total liabilities increased by 65.04% in accounts payable, reaching 58,875,569.60 CNY, mainly due to increased payables for goods[46]. - The company's receivables decreased by 91.58% to 20,856,725.61 CNY due to adjustments in the new revenue recognition standards[44]. - Total liabilities increased from CNY 336,510,151.29 to CNY 349,872,694.40, an increase of about 4.0%[93]. - Total equity decreased from CNY 954,695,566.45 to CNY 902,691,450.08, a decline of approximately 5.5%[93]. Organizational Changes and Strategy - The company has implemented an internal organizational restructuring to enhance project management and decision-making efficiency[33]. - The company plans to raise funds through a non-public offering to support the development of innovative drug projects[34]. - The company has initiated arbitration proceedings to enforce compensation related to a major asset restructuring, with 25.25 million shares already repurchased[35]. - The company has confirmed that the actual net profit for the years 2016, 2017, and 2018 must not be less than RMB 100 million, RMB 123 million, and RMB 147 million respectively, with a cumulative net profit of at least RMB 370 million during the performance commitment period[56]. Compliance and Governance - The company did not report any significant risks or non-compliance issues during the reporting period[4]. - The report was not audited, and the board of directors confirmed the accuracy and completeness of the financial statements[4]. - The company has maintained compliance with relevant laws and regulations, ensuring no significant legal disputes or penalties affecting its operations[60]. - There are no major litigation or arbitration matters reported for the company during the reporting period[62]. Shareholder Information - The company reported a total share capital of 400,386,394 shares, with a change in the number of restricted shares due to the lifting of restrictions[72]. - The largest shareholder, Xinjiang Hualing Industrial Trade Group, holds 79,525,087 shares, representing 19.86% of total shares[80]. - Zhang Xiaoqing, a significant shareholder, reduced his holdings by 25,252,039 shares, ending with 47,576,489 shares, which is 11.88% of total shares[80]. - Xinjiang Baihua Village Co., Ltd. increased its holdings by 25,252,039 shares, now holding 25,252,039 shares, accounting for 6.31% of total shares[80]. Accounting Policies and Financial Instruments - The company adheres to the accounting policies and estimates in accordance with the Enterprise Accounting Standards, ensuring the financial statements reflect its financial position accurately[141]. - The company recognizes financial assets based on the expected consideration to be received, with initial recognition at fair value[162]. - Financial assets are classified into three categories: measured at amortized cost, measured at fair value with changes recognized in other comprehensive income, and measured at fair value with changes recognized in profit or loss[161]. - The company measures expected credit losses for receivables based on the entire duration, with specific loss rates for aging categories, such as 5.00% for within 1 year and 30.87% for 3-4 years[176]. Inventory and Assets Management - Inventory is classified into seven categories, including finished goods, raw materials, and work in progress[178]. - The company uses the weighted average method for inventory valuation upon issuance and utilization[179]. - The net realizable value of inventory is determined by estimating the selling price less estimated costs to complete and sell, with provisions for inventory write-downs made when net realizable value is lower than cost[181].

Financial Performance - Operating revenue fell by 33.80% to CNY 46,641,794.47 year-on-year[5] - Net profit attributable to shareholders decreased by 100.61%, resulting in a loss of CNY 153,698.53[5] - Basic earnings per share dropped by 94.55% to CNY 0.0036[5] - The company reported a significant decline in net profit, indicating challenges in the current market environment[5] - The company recorded a net profit decrease of 90.09% in investment income, dropping to RMB 0.52 million from RMB 5.29 million in the previous year, primarily due to the disposal of a subsidiary[16] - The company anticipates potential significant changes in net profit compared to the previous year, although specific forecasts were not provided[19] - Total operating revenue for Q1 2020 was ¥46,641,794.47, a decrease of 33.9% compared to ¥70,454,860.94 in Q1 2019[30] - Net profit for Q1 2020 was ¥1,454,817.41, a decrease of 94.5% from ¥26,308,541.27 in Q1 2019[32] - Total comprehensive income for Q1 2020 was ¥885,802.02, a decrease of ¥2,109,250.74 compared to Q1 2019[37] Assets and Liabilities - Total assets decreased by 0.70% to CNY 1,282,128,516.02 compared to the end of the previous year[5] - The company reported a significant decrease in cash reserves, with a year-end balance of RMB 24.85 million, down 51.39% from RMB 51.12 million at the beginning of the period[15] - Current assets totaled ¥595,814,854.07, slightly down from ¥599,439,079.01, indicating a decrease of about 0.4%[23] - Total liabilities rose from ¥336,510,151.29 to ¥341,248,010.17, an increase of about 1.1%[23] - The company's equity attributable to shareholders decreased from ¥954,695,566.45 to ¥940,880,505.85, a decline of approximately 1.5%[24] - Total liabilities as of Q1 2020 were ¥89,268,908.96, a slight decrease from ¥91,109,367.03 in the previous year[30] - Total liabilities were reported at ¥336,510,151.29, slightly decreasing from ¥336,539,853.91, indicating a change of 29,702.62[44] Cash Flow - Cash flow from operating activities improved by 56.28%, with a net cash flow of CNY -21,235,073.15[5] - Cash inflow from operating activities in Q1 2020 was ¥52,743,048.39, down 19.4% from ¥65,461,677.50 in Q1 2019[38] - Cash outflow from operating activities in Q1 2020 totaled ¥73,978,121.54, a decrease of 35.2% from ¥114,030,995.75 in Q1 2019[39] - Net cash flow from operating activities for Q1 2020 was ¥-21,235,073.15, an improvement from ¥-48,569,318.25 in Q1 2019[39] - Cash flow from investment activities in Q1 2020 was ¥-4,816,814.87, compared to ¥25,860,185.69 in Q1 2019[39] - Cash flow from financing activities in Q1 2020 was ¥-219,916.66, an improvement from ¥-2,912,231.22 in Q1 2019[39] - The ending cash and cash equivalents balance for Q1 2020 was ¥24,851,358.14, down from ¥74,758,012.05 in Q1 2019[39] Shareholder Information - The total number of shareholders reached 12,027 at the end of the reporting period[11] - The largest shareholder, Xinjiang Hualing Industrial Trade Group, holds 19.86% of shares[11] Inventory and Receivables - Accounts receivable increased by 66.04%, reaching RMB 23.77 million compared to RMB 14.31 million at the start of the period, primarily due to increased sales in pharmaceutical R&D projects[15] - The company’s inventory rose to RMB 247.75 million, an increase of 4.57% from RMB 236.93 million, reflecting adjustments in stock levels[14] - Inventory increased from ¥236,932,526.73 to ¥268,415,149.78, reflecting a growth of approximately 13.3%[22] Expenses - Sales expenses increased by 74.74% to RMB 1.33 million, driven by higher costs associated with sales activities and the consolidation of additional companies[16] - Financial expenses surged by 1161.25% to RMB 0.57 million, mainly due to unrecognized financing costs and increased interest expenses[16] - The company incurred management expenses of ¥15,373,837.32 in Q1 2020, an increase from ¥13,456,342.84 in Q1 2019[31] Other Financial Metrics - The weighted average return on equity decreased by 2.71 percentage points to 0.15%[5] - Non-recurring gains and losses amounted to CNY 1,608,515.94[8] - The company is currently in the process of fulfilling a compensation obligation related to a performance guarantee agreement, which is expected to impact future financial results[18]

Financial Performance - In 2019, the company's operating revenue was CNY 262,017,718.33, a decrease of 37.49% compared to CNY 419,189,442.94 in 2018[19] - The net profit attributable to shareholders in 2019 was CNY 34,384,702.06, a significant improvement of 105.09% from a loss of CNY 675,291,477.07 in 2018[19] - Basic earnings per share for 2019 were CNY 0.0860, a turnaround from a loss of CNY 1.6866 in 2018, marking a 105.10% increase[21] - The weighted average return on equity improved to 3.68% in 2019, an increase of 52.48 percentage points from -48.80% in 2018[21] - The company reported a net cash flow from operating activities of -CNY 6,795,414.33 in 2019, a decline of 108.44% compared to CNY 80,553,717.37 in 2018[19] - The cumulative distributable profit for the company was negative at -CNY 1,678,504,740.43, leading to no cash dividend distribution for 2019[5] - The company reported non-recurring gains of ¥27,073,595.13 for the year 2019, compared to ¥143,509,581.00 in 2018, indicating a significant decrease[25] Assets and Liabilities - The company's total assets at the end of 2019 were CNY 1,291,205,717.74, reflecting a 3.43% increase from CNY 1,248,330,745.21 in 2018[20] - The net asset attributable to shareholders increased to CNY 954,695,566.45, up 4.49% from CNY 913,643,129.67 in 2018[20] - The company recognized an impairment loss of 17.55 million yuan for the Huawai Pharmaceutical asset group, with a cumulative impairment provision of 1.548 billion yuan[34] - The company reported a goodwill impairment provision of 17.55 million, impacting profits significantly[62] - The company’s accounts payable decreased by 44.41% to 40.59 million compared to the previous period[65] Revenue Breakdown - Revenue from pharmaceutical R&D decreased by CNY 92.67 million to CNY 114.54 million, with a gross margin reduction of 2.43%[54] - Clinical trial revenue decreased by CNY 18.98 million to CNY 116.17 million, with a gross margin decrease of 0.4%[54] - Other pharmaceutical income from intermediates was CNY 1.59 million, a decrease of 36.24%[55] - Domestic sales revenue was CNY 262 million, with a gross margin of 48.49%, an increase of 1.83 percentage points year-on-year[55] Operational Changes and Strategies - The company plans to enhance its core competitiveness by increasing investment in innovative drug research and development, focusing on original innovative drugs as a market value hotspot[31] - The company aims to expand its clinical service business for innovative drugs and strengthen strategic cooperation with major pharmaceutical companies[43] - The company has established new subsidiaries, including Liwei Biopharmaceuticals and Xipuda Data Management Company, to enhance its drug research and data management capabilities[44] - The company has implemented a comprehensive budget management system to improve operational control and reduce non-operational expenses[42] - The company aims to strengthen risk prediction and control systems across various business segments, including drug research and clinical services, to ensure healthy operations[80] Corporate Governance and Compliance - The company has made significant changes to its governance structure, including the appointment of new directors and supervisors to align with its strategic goals[41] - The company confirmed that it will not engage in any drug research and development activities directly or indirectly in any region after the completion of the major asset restructuring[89] - The company will strictly adhere to the decision-making procedures for related party transactions and ensure timely disclosure of such transactions[88] - The company has committed to avoiding related party transactions post-restructuring to protect shareholder interests[90] - The company has established a commitment to comply with all relevant laws and regulations in its operations and transactions[92] Shareholder Information - The top shareholder, Xinjiang Hualing Industrial Trade Group Co., Ltd., holds 79,525,087 shares, representing 19.86% of the total shares[127] - The total number of ordinary shareholders as of the end of the reporting period is 12,915, an increase from 12,027 at the end of the previous month[125] - The total number of shares held by the top ten unrestricted shareholders is 129,000,000, indicating strong support from major investors[128] - The company has not disclosed any related party relationships among the top shareholders[128] Employee and Labor Information - The total number of employees in the parent company is 47, while the main subsidiaries employ 809, resulting in a total of 856 employees[149] - The professional composition includes 721 technical personnel, 63 administrative staff, and 14 sales personnel[149] - The total remuneration paid to directors, supervisors, and senior management during the reporting period is 438.5[146] - The company has implemented a composite compensation system consisting of basic salary, performance pay, and various subsidies, ensuring timely and full payment of social insurance and housing fund for employees[150] Internal Control and Audit - The internal control evaluation report confirms the effectiveness of the company's internal control system as of December 31, 2019[162] - The company has established a self-evaluation and internal audit mechanism to address any identified internal control deficiencies promptly[180] - The audit report confirmed that the financial statements fairly reflect the company's financial position as of December 31, 2019[187] - The company is committed to maintaining compliance with accounting standards and ensuring the accuracy of financial reporting[196]

Financial Performance - Operating revenue fell by 51.31% to CNY 34,305,703.24 year-on-year[5] - Net profit attributable to shareholders decreased by 89.31% to CNY 2,830,693.04 compared to the same period last year[5] - Basic earnings per share dropped by 89.26% to CNY 0.0071[5] - The company reported a significant decline in net profit due to reduced operating revenue and increased costs[5] - Total operating revenue for Q1 2020 was ¥34,305,703.24, a decrease of 51.3% compared to ¥70,454,860.94 in Q1 2019[30] - Net profit for Q1 2020 was ¥2,830,693.04, a decline of 89.2% from ¥26,308,541.27 in Q1 2019[31] - Operating profit for Q1 2020 was ¥2,537,849.33, down 91.5% from ¥29,788,442.90 in Q1 2019[31] - Other income for Q1 2020 was ¥696,413.61, a decrease from ¥1,558,786.00 in Q1 2019[31] Assets and Liabilities - Total assets decreased by 3.66% to CNY 1,243,956,919.75 compared to the end of the previous year[5] - The company's cash and cash equivalents decreased by 51.39% to CNY 24.85 million from CNY 51.12 million at the beginning of the period[15] - Accounts receivable decreased significantly by 89.58% to CNY 25.40 million from CNY 235.08 million[21] - Inventory increased by 20.00% to CNY 284.87 million from CNY 236.93 million[14] - Total liabilities decreased by 32.08% to CNY 8.50 million from CNY 12.54 million[14] - Total assets decreased from CNY 1,291,205,717.74 to CNY 1,243,956,919.75, a decline of approximately 3.65%[24] - Current liabilities increased from CNY 270,933,683.21 to CNY 318,308,190.68, an increase of about 17.54%[23] - Total liabilities rose from CNY 336,510,151.29 to CNY 384,408,940.08, reflecting an increase of around 14.23%[23] - The company's equity attributable to shareholders decreased from CNY 954,695,566.45 to CNY 859,547,979.67, a decline of about 9.95%[24] Cash Flow - Cash flow from operating activities improved by 56.28%, reaching a net cash flow of -21,235,073.15[5] - Cash inflow from operating activities in Q1 2020 was CNY 52,743,048.39, down 19.4% from CNY 65,461,677.50 in Q1 2019[37] - Cash outflow from operating activities in Q1 2020 totaled CNY 73,978,121.54, a decrease of 35.2% from CNY 114,030,995.75 in Q1 2019[37] - Net cash flow from operating activities was negative CNY 21,235,073.15, an improvement from negative CNY 48,569,318.25 in Q1 2019[37] - Cash flow from investing activities was negative CNY 4,816,814.87 in Q1 2020, compared to a positive cash flow of CNY 25,860,185.69 in Q1 2019[38] - The company reported a net cash outflow of CNY 26,271,804.68 in Q1 2020, compared to a net outflow of CNY 25,621,363.78 in Q1 2019[38] Shareholder Information - The total number of shareholders reached 12,027[11] - The largest shareholder, Xinjiang Hualing Industrial Trade Group, holds 19.86% of shares[11] Expenses - The company reported a 74.74% increase in selling expenses to CNY 1.33 million compared to CNY 0.76 million in the previous year[16] - Financial expenses surged by 1161.25% to CNY 0.57 million from CNY 0.04 million year-over-year[16] - The company experienced a 75.92% reduction in income tax expenses to CNY 0.83 million from CNY 3.44 million[17] - Management expenses for Q1 2020 were ¥15,373,837.32, an increase of 14.2% compared to ¥13,456,342.84 in Q1 2019[31] Other Financial Metrics - Non-recurring gains and losses totaled CNY 1,608,515.94[8] - Investment income decreased by 90.09% to CNY 0.05 million from CNY 0.53 million in the previous year[16] - Long-term equity investments remained relatively stable, with a slight increase from CNY 51,503,259.60 to CNY 51,529,307.19[22] - The company has a long-term equity investment valued at 51,503,259.60 RMB[44]

2019 年第三季度报告 公司代码：600721 公司简称：*ST 百花 新疆百花村股份有限公司 2019 年第三季度报告 1 / 23 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 7 | | 四、 | 附录 | 9 | 2019 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人郑彩红、主管会计工作负责人蔡子云及会计机构负责人（会计主管人员）余涛保 证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 3 / 23 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 1,211,038,006.95 1,248,330,745.21 -2.99 归属于上市公司 股东的净资产 ...